Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing

Journal of Oncology Practice

Volumn 7, Issue 1, 2011, Pages 13-17

  Lopes Serrao, By Monique D ^a   Ussery, Sarah M Gressett ^a   Hall II, Ronald G ^a   Shah, Sachin R ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BODY MASS; BODY SURFACE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG CANCER; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OBESITY; PROSTATE CANCER;

EID: 79955681195     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2010.000045     Document Type: Article

References (27)

1. Flegal KM, Carroll MD, Ogden CL, et al: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727, 2002
2. Ogden CL, Carroll MD, Curtin LR, et al: Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555, 2006
3. Calle EE, Kaaks R: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591, 2004 (Pubitemid 39025053)
4. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215-244, 2000 (Pubitemid 32275588)
5. Prisco M, Romano G, Peruzzi F, et al: Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res 31:80-89, 1999 (Pubitemid 29169480)
6. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279:563-566, 1998 (Pubitemid 28067285)
7. Kaaks R, Toniolo P, Akhmedkhanov A, et al: Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592-1600, 2000
8. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, et al: Circulating levels of insulin-like growth factor I, its binding proteins-1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 106:90-95, 2003 (Pubitemid 36750393)
9. Palmqvist R, Hallmans G, Rinaldi S, et al: Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: A prospective study in northern Sweden. Gut 50:642-646, 2002 (Pubitemid 34407490)
10. Schairer C, Hill D, Sturgeon SR, et al: Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108:773-779, 2004 (Pubitemid 38076411)
11. Stattin P, Bylund A, Rinaldi S, et al: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study. J Natl Cancer Inst 92:1910-1917, 2000 (Pubitemid 32036921)
12. Berclaz G, Li S, Price KN, et al: Body mass index as a prognostic feature in operable breast cancer: The International Breast Cancer Study Group experience. Ann Oncol 15:875-884, 2004 (Pubitemid 39004342)
13. Fleming ST, Pursley HG, Newman B, et al: Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care 43:132-140, 2005 (Pubitemid 40222631)
14. De Jonge ME, Mathǒt RA, Van Dam SM, et al: Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 50:251-255, 2002 (Pubitemid 35013664)
15. Lind MJ, Margison JM, Cerny T, et al: Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25:139-142, 1989 (Pubitemid 20009443)
16. Navarro WH: Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 31:961-966, 2003 (Pubitemid 36722406)
17. Powis G, Reece P, Ahmann DL, et al: Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20:219-222, 1987 (Pubitemid 17163398)
18. Rodvold KA, Rushing DA, Tewksbury DA: Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327, 1988
19. Sparreboom A, Wolff AC, Mathijssen RH, et al: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707-4713, 2007 (Pubitemid 350086471)
20. Rosner GL, Hargis JB, Hollis DR, et al: Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: Results from Cancer and Leukemia Group B study 8541. J Clin Oncol 14:3000-3008, 1996 (Pubitemid 26371459)
21. Georgiadis MS, Steinberg SM, Hankins LA, et al: Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst 87:361-366, 1995
22. Litton JK, Gonzalez-Angulo AM, Warneke CL, et al: Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26:4072-4077, 2008
23. Meyerhardt JA, Catalano PJ, Haller DG, et al: Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98:484-495, 2003 (Pubitemid 36885987)
24. Poikonen P, Blomqvist C, Joensuu H: Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol 40(1):67-71, 2001 (Pubitemid 32234595)
25. Poikonen P, Saarto T, Lundin J, et al: Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80:1763-1766, 1999 (Pubitemid 29389629)
26. Meyerhardt JA, Catalano PJ, Haller DG, et al: Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98:484-495, 2003 (Pubitemid 36885987)
27. Dooley MJ, Singh S, Poole SG, et al: Distribution and discordance of body surface area (BSA) and body mass index (BMI) in 4514 patients with malignancy: The utility of BMI to identify obese patients and its implications in BSA adjusted dosing of cytotoxics. Proc Am Soc Clin Oncol 21:90a, 2002 (abstr 356)